RE
TCRT icon

RBC Europe’s Alaunos Therapeutics TCRT Stock Holding History

RBC Europe’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-47
Closed -$17.6K – 1178
2020
Q3 		$17.6K Hold
47
– – ﹤0.01% 669
2020
Q2 		$23K Hold
47
– – ﹤0.01% 599
2020
Q1 		$17.1K Hold
47
– – ﹤0.01% 591
2019
Q4 		$33K Buy
+47
New +$32.3K ﹤0.01% 549

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

RBC Europe's TCRT Position: Q4 2020 in Review

RBC Europe sold out of Alaunos Therapeutics (TCRT) in Q4 2020, closing a stake of 47 shares — an estimated $17.6K sold.

RBC Europe first reported a position in TCRT in Q4 2019 and held it in 4 quarters. The position peaked at $33K in Q4 2019. 156 funds tracked by Wall St. Rank hold TCRT as of Q4 2020.

  • RBC Europe reported no remaining Alaunos Therapeutics position as of Q4 2020 after selling out during the quarter.
  • RBC Europe sold 47 Alaunos Therapeutics shares in Q4 2020, an estimated $17.6K.
  • RBC Europe first reported a position in Alaunos Therapeutics in Q4 2019 and held it in 4 quarters.
  • RBC Europe's Alaunos Therapeutics position peaked at $33K in Q4 2019.
  • 156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2020.

Based on RBC Europe's 13F filing for Q4 2020, filed 9 Nov 2023.